Taisho, Takeda Each Market OTC Anti-Smoking Patches In Japan
This article was originally published in PharmAsia News
Taisho Pharmaceutical plans to sell an anti-smoking patch in Japan ahead of Takeda Pharmaceutical's own plans to sell a similar treatment for nicotine addiction. Taisho, which codeveloped Ciganon CQ with the U.K.'s GlaxoSmithKline, said it plans to take advantage of the Health Ministry's recent lifting of a ban on such over-the-counter drugs. Takeda said it would market Johnson & Johnson's Nicorette Patch, but both treatments follow the first on the market, Novartis Pharma's Nicotinell, which began selling May 31, just after the ministry eased its regulation. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.